Expanding Sales in the U.S., a Priority Region
First written in FY2016. 9 of 29 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
Seikagaku moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Other".
- FY2026U.S. product trends diverged over the full yearAnnual report
「Our sales declined 4.4% year on year, mainly because of a decrease in Spartz FX, a joint-function improver sold in the U.S., despite an increase caused by the shipment timing of Gel-One, a joint-function improver sold in the U.S.」
In U.S. pharmaceuticals, the shipment-timing-related increase in Gel-One was offset by a decline in Spartz FX, resulting in a 4.4% year-on-year decrease in overseas pharmaceutical sales. - FY2026-H1U.S. sales diverged by productAnnual report
「Our sales declined 7.1% year on year, despite increases in Gel-One, a joint-function improver sold in the U.S., and China Alts, because of declines in Spartz FX, a joint-function improver sold in the U.S., and other products. The changes were mainly attributable to shipment timing.」
In overseas pharmaceuticals, Gel-One increased while Spartz FX and other products declined, producing divergent U.S.-related sales trends by product. Shipment timing was cited as the main factor. - FY2025U.S. trends diverged by productAnnual report
「For Gel-One sold in the U.S., local sales volumes declined, and our sales decreased year on year because the timing of some product shipments was pushed back to the following fiscal year. For Spartz FX sold in the U.S., local sales volumes were similar to the prior fiscal year, but our sales increased because of inventory adjustments by our commercial partner.」
U.S. results diverged by product: Gel-One’s local sales volumes and our sales declined, while Spartz FX had similar local sales volumes but higher sales to us. - FY2025-H1Lower local sales, but shipment rebound increased our salesAnnual report
「For Gel-One sold in the U.S., local sales volumes declined, but our sales increased year on year because of the rebound from lower shipments in the first quarter. For Spartz FX sold in the U.S., local sales volumes were similar to the prior-year period, but our sales increased because shipments had temporarily declined in the prior-year period.」
In U.S. pharmaceuticals, local sales volumes of Gel-One declined, but our sales increased because of the rebound from lower first-quarter shipments. Spartz FX showed similar local sales volumes, while our sales increased because of the prior-year shipment decline. - FY2024-Q3Recovery after system change, but sales and revenue declinedAnnual report
「Although Gel-One, a single-injection joint-function improvement agent in the U.S., has been gradually recovering from the impact of the insurance reimbursement system change implemented in July 2022, local sales volumes and company sales declined.」
Although a gradual recovery from the impact of the reimbursement system change was reported, Gel-One’s local sales volumes and company sales continued to decline. - FY2024-Q1SoftenedAnnual report
「Local sales volumes and company sales of Gel-One in the U.S. declined because of the change to the insurance reimbursement system implemented in July 2022.」
Both local sales volumes and company sales of Gel-One declined because of the change to the insurance reimbursement system. - FY2023-Q2SoftenedAnnual report
「Local sales volumes of Gel-One in the U.S. declined because of the system change concerning price disclosure implemented from July 2022. Our sales increased substantially because of the effect of the weaker yen.」
Gel-One’s U.S. local sales volumes declined because of the system change concerning price disclosure from July 2022, while company sales increased substantially because of the weaker yen. - FY2023-Q1SoftenedAnnual report
「Local sales volumes of Gel-One in the U.S. declined because of market trends ahead of the system change concerning price disclosure in July 2022 and the reaction to the increase in volumes as the market recovered from COVID-19 in the prior-year period. Our sales increased substantially because of higher shipment volumes due to shipment timing and the effect of the weaker yen.」
U.S. local sales volumes declined because of market trends ahead of the price-disclosure system change and the prior-year rebound, while company sales increased substantially because of shipment timing and the weaker yen. - FY2022-Q2RestatedAnnual report
「Local sales volumes and company sales of Gel-One in the U.S. increased, supported by the rebound from the market contraction caused by the spread of COVID-19 in the prior-year period and the success of the commercialization partner’s switching measures from competing products.」
The increase in Gel-One’s U.S. local sales volumes and company sales continued, driven by the rebound from the prior-year pandemic impact and switching measures from competing products. - FY2022-Q1AdvancedAnnual report
「Local sales volumes of Gel-One in the U.S. increased substantially, reflecting the rebound from the impact of postponed non-urgent medical procedures in the prior-year period and the success of switching measures from competing products. Company sales also increased in line with the higher local sales volumes.」
Gel-One’s U.S. local sales volumes and company sales both increased, supported by the rebound from the prior-year pandemic impact and successful switching measures. - FY2021RestatedAnnual report
「While the overall U.S. market declined sharply because of postponed non-urgent medical procedures and other effects of the spread of COVID-19, local sales volumes of Gel-One increased as the preference for products requiring fewer injections continued and the commercialization partner’s switching measures proved effective. Our sales declined mainly because of lower shipments in the first quarter due to the spread of COVID-19 and other factors.」
Against a declining overall market, local sales volumes of Gel-One increased, while company sales declined because of lower first-quarter shipments. - FY2021-Q3RestatedAnnual report
「Gel-One, a single-injection joint-function improvement agent in the U.S., was significantly affected by the spread of COVID-19 in the first quarter, but local sales volumes increased from the second quarter onward as postponements of non-urgent medical procedures were eased. Our sales declined mainly because of the substantial impact of lower first-quarter shipments.」
U.S. local sales volumes increased from the second quarter onward and the recovery continued through the end of the third quarter, while company sales declined because of lower first-quarter shipments. - FY2021-Q2AdvancedAnnual report
「As postponements of non-urgent medical procedures in the U.S. were gradually eased, local sales volumes of Gel-One, a single-injection joint-function improvement agent, increased. Our sales declined because of the impact of lower shipments in the first quarter.」
As postponed medical procedures were eased in the U.S., local sales volumes of Gel-One increased. Company sales declined because of lower first-quarter shipments. - FY2021-Q1SoftenedAnnual report
「Local sales volumes and company sales of Gel-One, a single-injection joint-function improvement agent in the U.S., declined because of urban lockdowns and postponements of non-urgent medical procedures resulting from the spread of COVID-19.」
For Gel-One, the target of U.S. sales expansion, local sales volumes and company sales declined because of lockdowns and postponed non-urgent medical procedures. - FY2020AdvancedAnnual report
「Local sales volumes and company sales of Gel-One, a single-injection joint-function improvement agent in the U.S., increased substantially as a result of obtaining preferred reimbursement from multiple insurers beginning in 2019 and measures by the commercialization partner to switch patients from competing products.」
For the full year, U.S. local sales volumes and company sales increased substantially, supported by preferred reimbursement from multiple insurers and switching measures from competing products. - FY2020-Q3RestatedAnnual report
「In addition to obtaining preferred reimbursement from multiple insurers beginning in 2019, progress with measures to switch patients from competing products resulted in substantial increases in local sales volumes and company sales of Gel-One in the U.S.」
The company continued to report substantial increases in sales volumes and revenue, driven by preferred reimbursement from multiple insurers and switching measures from competing products. - FY2020-Q2AdvancedAnnual report
「In addition to obtaining preferred reimbursement from multiple insurers beginning in 2019, measures to switch patients from competing products proved effective for Gel-One, a single-injection joint-function improvement agent in the U.S., resulting in substantial increases in local sales volumes and company sales.」
Preferred reimbursement from multiple insurers and successful switching measures from competing products led to substantial increases in local sales volumes and company sales. - FY2020-Q1AdvancedAnnual report
「In addition to the commercialization partner’s sales expansion measures, Gel-One benefited from obtaining preferred reimbursement from multiple private insurers beginning in 2019, resulting in higher local sales volumes and company sales.」
U.S. sales expansion benefited from the commercialization partner’s sales measures and preferred reimbursement from multiple private insurers beginning in 2019, which increased local sales volumes and company sales. - FY2019SoftenedAnnual report
「Local sales volumes of Gel-One, a single-injection joint-function improvement agent, increased steadily in the U.S., but the growth rate fell short of the target as market conditions became increasingly challenging.」
Local sales volumes increased, but worsening market conditions caused the growth rate to fall short of the target. - FY2019-Q3SoftenedAnnual report
「Against this backdrop, local sales of Gel-One, a single-injection joint-function improvement agent, increased as a result of our commercialization partner’s sales expansion measures, but our sales declined because of lower local selling prices and a shift in shipment timing to the fourth quarter.」
Local sales increased through the commercialization partner’s sales expansion measures, but lower prices and shipment timing shifts reduced the impact on company sales. - FY2019-Q2SoftenedAnnual report
「Local sales of Gel-One, a single-injection joint-function improvement agent, and our sales increased in the U.S., but their growth rates have gradually moderated.」
U.S. local sales and company sales of Gel-One increased, while the rate of increase gradually slowed. - FY2019-Q1Higher local sales, shipment timing shiftAnnual report
「Local sales of Gel-One, a single-injection joint-function improvement agent, increased in the U.S., but our sales declined because shipments were shifted to after the second quarter.」
U.S. local sales increased, while the company’s sales declined because of the shipment timing shift. The progress in sales expansion and the timing of its reflection in quarterly results are presented together. - FY2018-Q3AdvancedAnnual report
「Local sales volumes of Gel-One, a single-injection joint-function improvement agent, continued to increase in the U.S. Although local selling prices declined because of pricing measures for certain large customers, our sales increased due to higher shipments and the effect of the weaker yen.」
The company reported higher U.S. local sales volumes and company sales of Gel-One under its policy of expanding sales in the U.S. as a priority region. - FY2018-Q1RestatedAnnual report
「Under this plan, we aim to further expand sales in the U.S., our priority region, obtain Japanese approval and U.S. approval for SI-6603, a treatment for lumbar disc herniation, and enter new markets with existing products.」
The policy of expanding sales in the U.S. as a priority region is reiterated as a key item in the medium-term plan. - FY2017AdvancedAnnual report
「In November 2016, we entered into an exclusive U.S. sales agreement with the company for Visco-3, a three-injection joint-function improvement agent. Together with the five-injection joint-function improvement agent Gel-One?」
An exclusive U.S. sales agreement for Visco-3 was signed, creating a product lineup covering 3 different injection schedules alongside Gel-One and the 5-injection Gel-One? - FY2017-Q3RestatedAnnual report
「Under this plan, we aim to further expand sales in the U.S., our priority region, obtain Japanese approval and U.S. approval for SI-6603, a treatment for lumbar disc herniation, and enter new markets with existing products.」
The medium-term plan positioning the U.S. as a priority region and targeting sales expansion is reiterated. - FY2017-Q2AdvancedAnnual report
「Local sales of Gel-One, a single-injection joint-function improvement agent in the U.S., continued to grow, and our sales increased despite the impact of the stronger yen. We will continue to focus on supporting our commercialization partner’s activities and aim to further increase sales.」
U.S. local sales of Gel-One and the company’s sales continued to increase, and support for the commercialization partner’s activities remains ongoing. - FY2017-Q1AdvancedAnnual report
「U.S. sales of Gel-One, a single-injection joint-function improvement agent, continued to increase, helped by the expanded sales structure of our commercialization partner.」
Against the policy of expanding sales in the U.S. as a priority region, the company reported higher local sales of Gel-One. - FY2016First statedAnnual report
「Under this plan, we aim to further expand sales in the U.S., our priority region, obtain Japanese approval and U.S. approval for SI-6603, a treatment for lumbar disc herniation, and enter new markets with existing products.」
The U.S. is positioned as a priority region, with sales expansion and commercialization of new products at the center of the medium-term plan.